Bristol Myers Squibb's Cancer Breakthrough Could Have Implications Beyond Its Own Stock

Impact · against what's priced in

The Phase 3 success of BMY's Iza-bren provides a tangible path to mitigate the Revlimid patent cliff, though near-term EPS headwinds persist. For EXEL, the clinical validation of ADC mechanisms is a marginal positive, but it does not offset the fundamental risk of the CABOMETYX patent cliff or recent guidance cuts.

EXEL+0.10

Doesn't touch the price's assumptions

The price assumes

The full financial upside of zanzalintinib across renal cell carcinoma and lung cancer